Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NXC736 in healthy male subjects
NCT05079425Phase 1Completed
- Sponsor
- NextGen Bioscience
- Start
- Sep 2021
- Primary completion
- Nov 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of vonifimod in alopecia areata, pulmonary fibrosis (PF) and Nonalcoholic steatohepatitis (NASH) (3 arms), sponsored by NextGen Bioscience. Primary endpoints: Number of Participants with Adverse Events (AEs) at Day 49, Number of Participants with Serious Adverse Events (SAEs) at Day 49 and 3 more. Started Sep 2021; status: completed.
02
Drugs
vonifimod
03
Conditions
alopecia areatapulmonary fibrosis (PF)Nonalcoholic steatohepatitis (NASH)
Beyond the preview
Go deeper on NCT05079425.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05079425.